[Skip to Content]
[Skip to Content Landing]
Research Letter
January 2017

Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma

Author Affiliations
  • 1Department of Dermatology, Stanford University School of Medicine, Redwood City, California
  • 2Department of Medicine–Head and Neck Oncology, Stanford University School of Medicine, Stanford, California
JAMA Dermatol. 2017;153(1):92-94. doi:10.1001/jamadermatol.2016.3884

Cutaneous squamous cell carcinoma (CSCC) is one of the 2 most common types of human malignant tumors.1 Although most CSCCs are effectively treated with excision, recurrent disease near vital structures or metastasis can be challenging to treat. Currently, there is no accepted standard of care for unresectable or metastatic CSCCs, although platinum compounds, taxanes, and fluorouracil are commonly used. Recently, 2 reports of CSCC cases treated with programmed cell death 1 (PD-1) inhibitors have been published but contain limited follow-up times (<7 months).2,3 The safety profile of PD-1 inhibitors in CSCCs is also not well known. We present 6 consecutive cases of advanced CSCCs treated with PD-1 inhibitors, including an extended follow-up of 1 previously reported index case2 to 21 months of progression-free survival (PFS).

First Page Preview View Large
First page PDF preview
First page PDF preview
×